These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15668752)

  • 41. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis.
    Ortonne JP
    J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():12-6. PubMed ID: 12795770
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
    Ellis CN; Krueger GG;
    N Engl J Med; 2001 Jul; 345(4):248-55. PubMed ID: 11474662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
    Lebwohl M; Christophers E; Langley R; Ortonne JP; Roberts J; Griffiths CE;
    Arch Dermatol; 2003 Jun; 139(6):719-27. PubMed ID: 12810502
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Psoriasis responds to intralesional injections of alefacept and may predict systemic response to intramuscular alefacept: interim results of a single-arm, open-label study.
    Gattu S; Busse K; Bhutani T; Chiang C; Nguyen T; Becker E; Koo JY
    J Dermatolog Treat; 2012 Apr; 23(2):103-8. PubMed ID: 21254875
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current concepts and review of alefacept in the treatment of psoriasis.
    Krueger GG
    Dermatol Clin; 2004 Oct; 22(4):407-26, viii. PubMed ID: 15450337
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alefacept - a drug review.
    Lev-Tov H; Hadi S
    Rev Recent Clin Trials; 2006 May; 1(2):163-4. PubMed ID: 18473967
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis.
    Perlmutter A; Cather J; Franks B; Jaracz E; Menter A
    J Am Acad Dermatol; 2008 Jan; 58(1):116-24. PubMed ID: 17997502
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alefacept treatment for chronic plaque psoriasis.
    Dunn LK; Feldman SR
    Skin Therapy Lett; 2010 Apr; 15(4):1-3. PubMed ID: 20361167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The AWARE study: methodology and baseline characteristics.
    Bissonnette R; Searles G; Landells I; Shear NH; Papp K; Lui H; Gulliver WP; Lynde C
    J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S113-21. PubMed ID: 20053323
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy.
    Lowe NJ; Gonzalez J; Bagel J; Caro I; Ellis CN; Menter A
    Int J Dermatol; 2003 Mar; 42(3):224-30. PubMed ID: 12653922
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
    Ortonne JP; Khemis A; Koo JY; Choi J
    J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):556-63. PubMed ID: 16164708
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.
    Menter A; Cather JC; Baker D; Farber HF; Lebwohl M; Darif M
    J Am Acad Dermatol; 2006 Jan; 54(1):61-3. PubMed ID: 16384756
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness and impact on quality of life of alefacept in the treatment of psoriasis.
    Scheinfeld N; Parish D
    Expert Rev Pharmacoecon Outcomes Res; 2007 Dec; 7(6):545-57. PubMed ID: 20528318
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.
    Krueger GG; Papp KA; Stough DB; Loven KH; Gulliver WP; Ellis CN;
    J Am Acad Dermatol; 2002 Dec; 47(6):821-33. PubMed ID: 12451365
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and efficacy of alefacept in elderly patients and other special populations.
    Gottlieb AB; Boehncke WH; Darif M
    J Drugs Dermatol; 2005; 4(6):718-24. PubMed ID: 16302557
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Understanding the new clinical landscape for psoriasis: a comparative review of biologics.
    Sauder DN; Mamelak AJ
    J Cutan Med Surg; 2004; 8(4):205-12. PubMed ID: 16091996
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monitoring patients treated with efalizumab or alefacept.
    Papp KA
    Curr Probl Dermatol; 2009; 38():95-106. PubMed ID: 19710552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Open-label, single-center, safety dose escalation trial of alefacept for the treatment of moderate to severe chronic plaque psoriasis.
    Moul DK; Routhouska SB; Korman NJ
    J Cutan Med Surg; 2007; 11(4):132-6. PubMed ID: 17601420
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alefacept modifies long-term disease severity and improves the response to other treatments.
    van Duijnhoven MW; de Jong EM; Gerritsen WJ; Pasch MC; van de Kerkhof PC
    Eur J Dermatol; 2005; 15(5):366-73. PubMed ID: 16172047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.